Overview

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.

Phase:

Phase 3

Details

Lead Sponsor:

Bioeq GmbH

Treatments:

Aflibercept